Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.
OBJECTIVE
To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose.


METHODS
Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later.


RESULTS
3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment.


CONCLUSIONS
Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.
Buijs
Manon
M
Russell H. Morgan Department of Radiology, and Radiological Sciences, Division of Vascular and Interventional Radiology, 600 North Wolfe Street, Blalock 545, Baltimore, MD 21287, USA.
Vossen
Josephina A
JA
Geschwind
Jean-Francois H
JF
Ishimori
Takayoshi
T
Engles
James M
JM
Acha-Ngwodo
Obele
O
Wahl
Richard L
RL
Vali
Mustafa
M
D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006019:Glycolysis / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D011773:Pyruvates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew
D011773:Pyruvates; D019788:Fluorodeoxyglucose F18; C017092:bromopyruvate